Please assess the completion status of the following clinical trial:

Trial Title: Low-dose Molecular Breast Imaging: Comparison of Breast Cancer Detection Rate at Initial Screening and Two-year Follow-up

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~- Past prior screening mammogram within the previous 11-24 months interpreted as heterogeneously dense or extremely dense and negative or benign \[Breast Imaging Reporting and Data System (BI-RADS) Category 1 or 2\]~Exclusion Criteria:~Subjects will be excluded if they:~* Are unable to understand and sign the consent form~* Are pregnant or lactating~* Are physically unable to sit upright and still for 40 minutes~* Have self-reported signs or symptoms that may suggest breast cancer (palpable mass, bloody nipple discharge, axillary mass, etc.)~* Have had needle biopsy within 3 months, or breast surgery or radiation within 1 year prior to the study~* Are currently receiving chemotherapy or tamoxifen, raloxifene, or an aromatase inhibitor for adjuvant therapy or chemoprevention~* Have undergone bilateral mastectomy~* Have had a prior MBI within 20 months of scheduled study MBI.

- Gender: FEMALE
- Minimum Age: 40 Years
- Maximum Age: 80 Years
- Healthy Volunteers: t

Study Arms:
- Molecular Breast Imaging (Type: EXPERIMENTAL): Molecular Breast Imaging (MBI) utilizes small high resolution gamma camera detectors in a dual-detector configuration to image the breast following the administration of a radiopharmaceutical that accumulates preferentially in breast tumors.

Based on this trial design, predict the completion outcome and termination type (if applicable).